FGFR1 and alopecia: According to the central review committee, 24 (77.4%) patients had a CR with a cytogenetic complete response observed in 24 (75.8%) patients.33 An updated analysis reported that among patients with a CR, 81% and 47.6% had a >3-log and >2-log reduction in FGFR1 fusion transcripts by PCR, respectively.34 The most common treatment-related AEs were hyperphosphatemia (73%), alopecia (56%), and diarrhea (56%), and no patients had grade 3 or higher hyperphosphatemia.35